

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2778131

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
IRUN R. COHEN	02/05/2014
FELIX MOR	02/05/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	STEM CELL MEDICINE LTD.
<b>Street Address:</b>	5 KIRYAT MADA STREET
<b>Internal Address:</b>	HAR-HOZVIM
<b>City:</b>	JERUSALEM
<b>State/Country:</b>	ISRAEL
<b>Postal Code:</b>	9777605
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>PCT Number:</b>	IL2012050378
<b>Application Number:</b>	14346219
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)783-6031
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2027836040
<b>Email:</b>	jfu@rfem.com
<b>Correspondent Name:</b>	ROTHWELL, FIGG, ERNST & MANBECK, P.C.
<b>Address Line 1:</b>	607 14TH STREET, N.W.
<b>Address Line 2:</b>	SUITE 800
<b>Address Line 4:</b>	WASHINGTON, DISTRICT OF COLUMBIA 20005
<b>ATTORNEY DOCKET NUMBER:</b>	3596-165
<b>NAME OF SUBMITTER:</b>	GEORGE R. REPPER, REG. NO. 31,414
<b>SIGNATURE:</b>	/George R. Repper/
<b>DATE SIGNED:</b>	03/20/2014
<b>Total Attachments: 3</b>	
source=3596-165 Assignment#page1.tif	
source=3596-165 Assignment#page2.tif	



## ASSIGNMENT

This Assignment is made and executed by:

Irur R. COHEN  
11 Hankin Street,  
76354 Rehovot,  
Israel

Felix MOR  
3 Mishol Hachen Street  
44419 Kfar Saba,  
Israel

(hereinafter "Assignors"), to and in favor of Stem Cell Medicine Ltd. having a business address of 5 Kiryat Mada Street, Har-Hozvim, 9777605 Jerusalem, Israel (hereinafter "Assignee").

Whereas each of the Assignors desires to assign his entire right, title and interest in and to the invention described in the non-provisional patent application for a United States Patent entitled "BETA-LACTAM COMPOUNDS FOR TREATING DIABETES" which claims priority to as a 371 of international of PCT/IL2012/050378, filed on September 20, 2012, which claims priority to US provisional patent application number 61/537,105, filed on September 21, 2011 (hereinafter the "Patent Application") and all patents, patent applications and the like on the invention to Assignee for valuable consideration; and

Whereas Assignee has provided such valuable consideration to the Assignors;

Accordingly, Assignors each warrant, covenant and agree as follows:

1. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in and to the invention described in the Patent Application, including the Patent Application itself and all substitute, continuation, continuation-in-part and divisional applications based in whole or in part on the Patent Application, and including all patents resulting therefrom and all reissues and extensions thereof, and including any and all rights of priority resulting from the filing of any such applications within the United States.

2. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in all counterparts to the Patent Application that have been or may be filed outside the United States or under the Patent Cooperation Treaty, whether pursued as a patent, an inventor's certificate, a utility model or the like, including all rights of priority based on the Patent Application, further including all continuation, continuation-in-part and divisional applications based in whole or in part on the non-U.S. counterparts, and still further including all patents, inventor's certificates, utility models, reissues and extensions resulting from any of the non-U.S. counterparts.

ASSIGNMENT

Docket No. \_\_\_\_\_

Title: "BETA-LACTAM COMPOUNDS FOR TREATING DIABETES "

U.S. Serial No.

3. Each of the Assignors hereby grants to Assignee the sole and exclusive right to prosecute the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as any opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings. Each of the Assignors authorizes all governmental bodies having the power to issue patents, inventor's certificates or utility models to issue a patent, inventor's certificate or utility model based on the Patent Application or any related applications as described in Paragraphs 1 and 2 above in the name of Assignee.

4. Each of the Assignors agrees upon request and without further consideration, but at Assignee's expense: (a) to assist Assignee in prosecuting the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings; (b) to provide Assignee with information concerning the Patent Application and the related applications described in Paragraphs 1 and 2 above to enable Assignee to obtain, secure and protect all of the rights, title and interest sold, assigned, conveyed and granted under this Assignment (the "Assigned Assets"); (c) to sign papers, take oaths and testify in legal proceedings to enable Assignee to obtain, secure and protect the Assigned Assets; and (d) to perform all acts reasonably necessary to enable Assignee to obtain, secure and protect the Assigned Assets, including assistance in any proceedings pertaining to the Patent Application and the related applications described in Paragraphs 1 and 2 above or to their enforcement.

5. Each of the Assignors warrants and covenants that such Assignor has the full right to sell, assign and convey the Assigned Assets, that all of the Assigned Assets are free and clear of all mortgages, liens, security interests, charges, claims, royalty obligations and encumbrances of any nature whatsoever and that the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

6. Assignee may assign the Assigned Assets in whole or in part. All references herein to Assignee include any successors or assigns of Assignee.

7. Each of the Assignors acknowledges that Assignee has paid valuable consideration for the Assigned Assets.

8. Each of the Assignors hereby authorizes any member of the firm of Rothwell, Figg, Ernst & Manbeck, P.C. to insert or complete any information, including but not limited to the patent

ASSIGNMENT

Docket No. \_\_\_\_\_

Title: "BETA-LACTAM COMPOUNDS FOR TREATING DIABETES "

U.S. Serial No.

- application serial number, needed to effect this document's recordation in the United States  
· Patent and Trademark Office.

5-2-2014

Date



Irvin R. COHEN

Maya Dozen

Witness

5-2-2014

Date



Felix MOR

Maya Dozen

Witness